Introduction
============

Hypersomnias are one of the important classes of sleep disorders, patients are manifested by recurring episodes of excessive daytime sleepiness (EDS) that are not due to tiredness. Hypersomnia can be a symptom of other sleep disorders such as narcolepsy with cataplexy, essential hypersomnia (EHS), sleep apnea and idiopathic hypersomnia.

In 1986, Yutaka Honda described a group of patients with a narcolepsy-like condition that lacked cataplexy; he designated this condition essential hypersomnia syndrome (EHS) ([@ref-16]). EHS is characterized by excessive daytime sleepiness features that are indistinguishable from those of narcolepsy such as shorter episodes of irresistible daytime sleepiness, feelings of refreshment after short naps, and the absence of prolonged nocturnal sleep time. Patients with EHS show frequent sleep-onset rapid eye movement (REM) periods (SOREMPs) when a multiple sleep latency test (MSLT) is performed ([@ref-1]). Honda and his colleagues later reported that the symptomatic characteristics of these patients are different from those of patients with classical idiopathic hypersomnia syndrome (IHS); reportedly, IHS sleep patterns include long naps and prolonged nocturnal sleep ([@ref-33]). Based on the criteria in the International Classification of Sleep Disorders second edition (ICSD-2) ([@ref-2]), the diagnostic criteria for EHS correspond to those for narcolepsy without cataplexy and most of those for IHS without long sleep. Previously we showed that approximately 40% of the patients with EHS carry the *HLA-DQB1\*06:02* allele but that 12% of the general Japanese population and 100% of the patients with narcolepsy with cataplexy carry this allele ([@ref-29]; [@ref-23]). Additionally several reports from other groups also indicate that *HLA-DQB1\*06:02* is associated with the pathogenesis of narcolepsy with cataplexy ([@ref-22]; [@ref-17]; [@ref-21]); given these finding, we believe that the pathogenesis of EHS may partially differ from that of narcolepsy with cataplexy. In addition, study has also suggested that EHS is likely to be a member of hypersomnia based on the differences in genetic composition of EHS and narcolepsy with cataplexy, milder disease severity of EHS, and the superior treatment response of EHS ([@ref-29]). Based on Epworth Sleepiness Scale (ESS) and MSLT evaluations, the severity of EDS is significantly milder in EHS than in narcolepsy with cataplexy ([@ref-18]).

Several studies carried out by our group demonstrate that common susceptibility genes exist between *HLA-DQB1\*06:02* positive EHS and narcolepsy with cataplexy patients, suggesting a common etiological pathway might exist for *HLA-DQB1\*06:02* positive EHS and narcolepsy with cataplexy patients. For example, *TCRA* is reported to be strongly associated with narcolepsy with cataplexy ([@ref-14]) and our replication study indicated that *TCRA* is also associated with *HLA-DQB1\*06:02* positive EHS ([@ref-24]). In contrast, *CPT1B* and *CHKB*, which are reportedly associated with narcolepsy with cataplexy in a Japanese population ([@ref-26]), are also reportedly associated with both *HLA-DQB1\*06:02*-positive EHS and EHS in patients lacking *HLA-DQB1\*06:02* (designated here as *HLA-DQB1\*06:02*-negative EHS) ([@ref-23]). Taken together these findings indicate that *CPT1B* and *CHKB* have a broader functional role in hypersomnias as general.

Based on the hypothesis that *HLA-DQB1\*06:02* negative EHS has a different etiological pathway from that of narcolepsy with cataplexy, we aimed to identify commonly occurring genetic variants that are associated with susceptibility to *HLA-DQB1\*06:02* negative EHS in a Japanese study population. To our knowledge, there is no published report of a genome-wide association study (GWAS) on any hypersomnia in any human population other than those GWASs on narcolepsy with cataplexy.

Materials and Methods
=====================

Subjects
--------

EHS was diagnosed based on the following three clinical items in central nervous system hypersomnias: (i) recurrent daytime sleep episodes that occur basically everyday over a period of at least 6 months; (ii) absence of cataplexy; (iii) the hypersomnia is not better explained by another sleep disorder, medical or neurological disorder, mental disorder, medication use or substance use disorder ([@ref-29]; [@ref-18]; [@ref-23]; [@ref-16]). We focused our studies on patient with EHS, but lacking *HLA-DQB1\*06:02*, because previous studies ([@ref-24]; [@ref-16]; [@ref-29]) indicated that *HLA-DQB1\*06:02* negative EHS is essentially different from HLA-positive EHS and narcolepsy with cataplexy. In this GWAS, we recruited 125 individuals who were given a diagnosis of EHS at a clinic affiliated with Neuropsychiatric Research Institute of Japan and 562 Japanese individuals as healthy controls. All genomic DNA samples were genotyped using Affymetrix Genome-Wide SNP Array 6.0 platform. In order to validate the accuracy of the top SNPs from the Affymetrix Genome-Wide SNP Array 6.0 platform, three SNPs (rs11854769, rs12471007 and rs10988217) were genotyped by TaqMan assay.

In order to elucidate the effects of susceptibility SNPs found in Japanese EHS GWAS samples in other population, a collaboration study with the Center for Narcolepsy, Stanford University School of Medicine, was carried out. The comparative study of a Caucasian population focused on patients with 268 *HLA-DQB1\*06:02*-negative hypersomnias and 1761 *HLA-DQB1\*06:02*-negative healthy controls. All subjects had given written informed consent for their participation in these studies in accordance with the process approved by ethics committees of the University of Tokyo and Stanford University.

HLA genotyping
--------------

*HLA-DQB1* genotyping for EHS samples were performed using Luminex Multi-Analyte Profiling System (xMAP) together with the WAKFlow HLA typing kit (Wakunaga, Hiroshima, Japan). Briefly, target DNA was amplified by PCR (polymerase chain reaction) with biotinylated primers. The PCR amplicon was then denatured and hybridized to complementary oligonucleotide probes immobilized on fluorescent coded microsphere beads. In the meantime, biotinylated PCR products were labeled with phycoerythrin-conjugated streptavidin, and finally HLA typing was examined by Luminex 100 (Luminex, Austin, TX).

Genotyping and quality control
------------------------------

Genotype calling was performed using Affymetrix Genotyping Console 4.0, which employs the Birdseed genotype calling algorithm for Affy 6.0 (*n* = 687). Samples with a low quality control call rate (typically \<95%) were excluded before performing the full clustering analysis of genotypes. For each Birdseed genotype call, SNPs with call rates \<99%, SNP that shown deviation from Hardy-Weinberg (*P* \< 0.001) in controls, monomorphic SNP, and sex-chromosome SNPs were excluded from subsequent analysis. Cluster plots of the top 100 SNPs that showed the strongest association were checked visually and ambiguously clustered SNPs were excluded; only one SNP was excluded based on this cluster criterion. In the absent of independent Japanese EHS samples for replication, we validated the accuracy of randomly selected SNPs genotyped by Affymetrix 6.0 platform using a TaqMan assay.

Statistical analysis
--------------------

Association analysis of SNPs were analyzed using an allelic model, a dominant model, a recessive model, or a Cochran--Armitage trend test using PLINK (v1.07) ([@ref-32]). Population stratification within the Japanese patients with EHS was evaluated based on the genomic inflation factor (λ), which was calculated from the median of the Cochran--Armitage trend test. The quantile-quantile (Q--Q) plot was plotted with expected distribution of association test statistics under null distribution across the Cochran--Armitage trend observed *P*-values with *R* statistical environment version 2.9.0. Peta odd ratio was used to calculate odd ratio for any contingency column with counting of 0, online calculator is available at <http://www.hutchon.net/ConfidORnulhypo.htm>. Manhattan-plot was generated using Haploview (v4.1) ([@ref-4]). For the Caucasian comparative study, an allelic, a dominant, and a recessive model were each assessed using a 2-tailed chi-square test. The eQTL analyses were performed based on data from the Sanger Institute GENEVAR project ([@ref-38]); these data are based on three cell types (fibroblast, lymphoblastoid cell line and T-cell) of 75 unrelated Western European origin individuals ([@ref-11]). The SNPExpress Database ([@ref-15]), which is based on 93 autopsy-collected cortical brain tissue with no defined neuropsychiatric condition and 80 peripheral blood mononucleated cell (PMBC) samples collected from healthy donors, was also used as a reference for eQTL analyses. Relationships between the genotypes of candidate loci and the expression levels of nearby genes and transcripts were also examined.

Imputation
----------

MACH version 1.0 ([@ref-20]) was used to estimate haplotypes, map crossover and error rates using 50 iterations of the Markov chain Monte Carlo algorithm. By employing genotype information from HapMap Phase II (release 23) database ([@ref-10]), maximum likelihood genotypes were generated. For the quality control of the imputed genotypes, imputed genotypes with the estimated *r*2 \> 0.3 were retained. Imputed genotypes were re-analyzed by allelic, dominant, and recessive models and the Cochran--Armitage trend test utilizing PLINK 1.7. Regional association plots were generated using LocusZoom ([@ref-31]).

Results
=======

This is the first reported GWAS that aimed to identify common genetic variants associated with *HLA-DQB1\*06:02* negative EHS. Specifically, we sought to identify susceptibility loci, other than HLA loci, for EHS using a collection of samples that lacking the *HLA- DQB1\*06:02*. For this GWAS, we recruited 125 individuals who were given a diagnosis of EHS at a clinic that is affiliated with the Neuropsychiatric Research Institute of Japan and 562 Japanese healthy controls. Genomic DNA samples from each individual were genotyped using the Affymetrix Genome-Wide SNP Array 6.0 platform. After quality controls (see Methods for details), statistical tests were performed on 508,366 remaining SNPs. Population stratification was accessed by calculating the genomic inflation factor (λ); the λ of this data set was 1.008; this finding indicated that errors resulting from population stratification, cryptic relatedness, or both were unlikely ([Fig. S1](#supp-1){ref-type="supplementary-material"}). A genome-wide Manhattan plot was drawn using the chromosomal positions of individual SNPs (*x*-axis) and the negative logarithm of *P* values calculated with the Cochran--Armitage trend test (*y*-axis) ([Fig. S2](#supp-2){ref-type="supplementary-material"}).

We identified one genomic region, 2q21.2, that contained clustered SNPs that were significantly associated (*P*-value \< 5 × 10^−7^) with increased risk of EHS in this Japanese population ([Fig. S2](#supp-2){ref-type="supplementary-material"} and [Table 1](#table-1){ref-type="table"}). Additionally, we chose to further investigate 9q34 because of its functional importance.

The SNP rs16826005 had the lowest *P*-value (1.02E-07, per-allele odds ratio (OR) of 1.89 with 95% confidence interval (CI) of 1.43--2.50) of all SNPs assessed; rs16826005 was located within a 19-kb linkage disequilibrium (LD) block on chromosome 2q21.2 ([Table 1](#table-1){ref-type="table"}). This LD-block covered the intronic region of *NCKAP5* (NCK-associated protein 5) gene. Imputation analysis of this region revealed modest associations between *HLA-DQB1\*06:02* negative EHS and SNPs in the *NCKAP5* gene. This finding indicated that *NCKAP5* may play a causative role in EHS pathogenesis. Expression data for *NCKAP5* is not readily available in the Gene Variation Database (GeneVar) ([@ref-38]) or the SNPExpress database ([@ref-15]).
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###### List of SNPs that show associations with increase risk of *HLA-DQB1\*06:02* negative EHS in the Japanese population.

![](peerj-01-66-g002)

  CHR   SNP                                                                               Risk   RAF     Allelic   Dominant   Recessive   *P* ~min~   Nearby Gene                                                                              
  ----- --------------------------------------------------------------------------------- ------ ------- --------- ---------- ----------- ----------- ------------- ---------- ------ ------ ------ ---------- ------ ------ ------ ---------- ---------------
  2     rs16826005                                                                        G      0.472   0.319     3.97E-06   1.89        1.43        2.50          7.51E-03   1.74   1.16   2.62   1.02E-07   3.52   2.17   5.70   1.02E-07   *NCKAP5*
  2     rs12471007[^\*^](#table-1fn4){ref-type="fn"} [^\#^](#table-1fn5){ref-type="fn"}   C      0.456   0.312     1.33E-05   1.86        1.41        2.46          1.86E-02   1.72   1.15   2.56   1.09E-07   4.11   2.55   6.60   1.09E-07   *NCKAP5*
  15    rs11854769[^\*^](#table-1fn4){ref-type="fn"}                                      T      0.316   0.177     6.69E-07   2.27        1.64        3.14          7.15E-06   2.43   1.64   3.59   3.61E-04   4.07   1.78   9.31   6.69E-07   *SPRED1*
  15    rs2174009                                                                         C      0.335   0.193     9.34E-07   2.24        1.62        3.10          1.02E-05   2.40   1.62   3.56   2.87E-04   3.90   1.78   8.56   9.34E-07   *SPRED1*
  15    rs16966389                                                                        G      0.804   0.642     7.52E-07   2.28        1.63        3.20          6.56E-07   2.73   1.82   4.10   1.07E-02   2.91   1.24   6.86   6.56E-07   *SPRED1*
  2     rs359268                                                                          C      0.584   0.431     1.16E-05   1.89        1.42        2.51          1.47E-02   1.79   1.12   2.88   1.00E-06   2.81   1.84   4.30   1.00E-06   *BCL11A*
  15    rs2134333                                                                         A      0.332   0.194     1.99E-06   2.19        1.58        3.02          2.05E-05   2.32   1.57   3.44   3.52E-04   3.83   1.75   8.40   1.99E-06   *SPRED1*
  5     rs7725217                                                                         C      0.352   0.223     1.96E-05   2.00        1.46        2.74          1.08E-06   2.66   1.78   3.98   4.08E-01   1.41   0.62   3.19   1.08E-06   *TAS2R1*
  9     rs10988217[^\*^](#table-1fn4){ref-type="fn"}                                      G      0.320   0.233     4.05E-03   1.52        1.13        2.04          2.55E-01   1.25   0.85   1.85   3.43E-06   3.85   2.11   7.04   3.43E-06   *PPP2R4/CRAT*
  2     rs2043234                                                                         T      0.359   0.224     8.22E-06   1.95        1.45        2.64          1.15E-03   1.91   1.29   2.83   4.46E-06   4.05   2.14   7.66   4.46E-06   *NCKAP5*

**Notes.**

RAF, risk allele frequency; OR, odd ratio; L95, U95, lower and upper confidence limits; *P*~min~, minimum *P*-value among three genetic models; NA: not applicable.

Recessive model is calculated under risk allele homozygotes versus (heterozygous and non-risk homozygotes).

Dominant model is calculated under (risk allele homozygotes and heterozygotes) versus non-risk homozygotes.

SNP count was reconfirmed by TaqMan platform.

SNP count adjusted for TaqMan platform.

Peta odd ratio was used to calculate odd ratio for any contingency column with counting of 0.

The SNP rs11854769 had the second lowest *P*-value by regional classification (6.69E-07, per-allele OR of 2.27 with 95% CI of 1.64--3.14) in this analysis. This SNP, rs11854769, resided within a 10 kb LD block on chromosome 15q14 ([Table 1](#table-1){ref-type="table"}) and was located 42 kb upstream of *SPRED1* (*sprouty-related, EVH1 domain containing 1*). Imputation analysis of this region did not reveal any additional SNPs that were more significantly associated with *HLA-DQB1\*06:02* negative EHS ([Fig. 1](#fig-1){ref-type="fig"}). An eQTL analysis showed that rs11854769 did not affect the expression level of *SPRED1* in either the GeneVar database or the SNPExpress database ([Fig. S4A](#supp-4){ref-type="supplementary-material"}).

![Regional association plots for three *HLA-DQB1\*06:02* negative EHS risk loci.\
(A) The region 2q21.2 Cochran--Armitage trend test *P*-value, the SNP rs16826003 is located in an intron of *NCKAP5* gene (B) The region 15q14 Cochran--Armitage trend test, SNP rs11854769 is located 42 kb upstream of the nearest gene, *SPRED1* (C) The 9q34 region based on P-minimum, rs10988217 is located in an intron of *CRAT* gene. Each of the top markers is indicated by purple diamonds. SNPs that were genotyped using Affymetrix 6.0 are marked by triangles. Imputed SNPs are plotted as circles. The color intensity represents the extent of the LD with the marker SNP, red (*r*^2^ ≥ 0.8), orange (0.6 ≤ 0.8), green (0.4 ≤ 0.6), light blue (0.2 ≤ 0.4), and dark blue (*r*^2^ ≤ 0.2). Light blue in the background indicates local recombination rate.](peerj-01-66-g001){#fig-1}

The SNP rs10988217 (*P*-value of 3.43E-06, per-allele OR of 1.52 with 95% CI of 1.13--2.04), which was located within a 63 kb LD block on chromosome 9q34.11, was also of interest ([Table 1](#table-1){ref-type="table"}). The associated SNP is located in the intronic region of *PPP2R4* (protein phosphatase 2A activator, regulatory subunit 4) and *CRAT* (carnitine O-acetyltransferase).The eQTL analysis revealed that rs10988217 affected the expression of *CRAT* transcripts in the SNPExpress database ([Fig. S4B](#supp-4){ref-type="supplementary-material"}), but not *PPP2R4* transcripts ([Fig. S4C](#supp-4){ref-type="supplementary-material"}). Similar findings were observed in the GeneVar database; rs10988217 was associated with *CRAT* expression levels (*P* \< 0.05) in three cell types (fibroblast, lymphoblastoid cell line and T-cell) ([Fig. S3B](#supp-3){ref-type="supplementary-material"}), but not with any changes in *PPP2R4* expression ([Fig. S3C](#supp-3){ref-type="supplementary-material"}).

A comparative study of Caucasian patients with *HLA-DQB1\*06:02* negative hypersomnia revealed that rs10988217, the SNP in the *PPP2R4*-*CRAT* region, was significantly associated with *HLA-DQB1\*06:02* negative hypersomnia in this population (*P*-value of 2.51E-02, per-allele OR of 1.25 with 95% CI of 1.03--1.52) ([Table 2](#table-2){ref-type="table"}); these finds were similar to those from the GWAS of Japanese patients with *HLA-DQB1\*06:02* negative EHS (*P*-value of 3.43E-06, per-allele OR of 1.52 with 95% CI of 1.13--2.04) ([Table 1](#table-1){ref-type="table"}). To investigate possible contributions of this SNP to other forms of hypersomnia, we tested the association of rs10988217 with narcolepsy with cataplexy in Japanese and Caucasian patients ([@ref-14]). Significant associations were observed in Japanese narcolepsy (*P*-value of 2.20E-02, per-allele OR of 1.22 with 95% CI of 1.03--1.45) and Caucasian narcolepsy (*P*-value of 2.82E-02, per-allele OR of 1.13 with 95% CI of 1.01--1.27) ([Table 3](#table-3){ref-type="table"}). Other SNPs that showed associations with an increased risk of EHS in the Japanese population were also genotyped in the samples from Caucasian patients with *HLA-DQB1\*06:02* negative hypersomnia, but no associations were found ([Table 2](#table-2){ref-type="table"}).
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###### List of SNPs of interest for *HLA-DQB1\*06:02* negative hypersomnias samples in Caucasian population.
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  SNP(A/B)           Risk allele   RAF     HWE *P*-values   Chi-square 2-tailed *P*-values   OR      L95        U95        Nearest gene                        
  ------------------ ------------- ------- ---------------- -------------------------------- ------- ---------- ---------- -------------- ------ ------ ------ ----------
  rs11854769 (C/T)   C             0.731   0.732            0.369                            0.263   9.70E-01   3.00E-01   6.20E-01       1.00   0.81   1.23   *SPRED1*
  rs16966290(C/A)    A             0.885   0.903            0.947                            0.286   2.30E-01   7.70E-01   1.70E-01       1.20   0.88   1.63   *SPRED1*
  rs12471007(C/G)    G             0.035   0.040            0.179                            0.501   5.50E-01   4.40E-01   4.50E-01       1.15   0.72   1.85   *NCKAP5*
  rs10988217(G/A)    G             0.597   0.648            0.581                            0.456   2.51E-02   3.00E-02   1.16E-01       1.25   1.03   1.52   *CRAT*

**Notes.**

RAF: Risk allele frequency, HWE: Hardy-Weinberg Equilibrium, OR: Odds ratio, L95, U95: lower and upper limits of confidence interval at 95%.

Recessive model is calculated under risk allele homozygotes versus (heterozygous and non-risk homozygotes).

Dominant model is calculated under (risk allele homozygotes and heterozygotes) versus non-risk homozygotes.

10.7717/peerj.66/table-3

###### GWAS and comparative studies for rs10988217 in Japanese and Caucasian populations.

![](peerj-01-66-g004)

  Subjects                                           Case count   Control count   AF (Case)   AF (Control)   Chi-Square 2-tailed *P*-value   *P* ~min~   OR    L95    U95                                                                                       
  -------------------------------------------------- ------------ --------------- ----------- -------------- ------------------------------- ----------- ----- ------ ------- ------- ------- ------- ---------- ---------- ---------- ---------- ------ ------ ------
  Japanese *HLA-DQB1\*06:02* negative EHS GWAS       21           38              66          125            28                              206         328   562    0.320   0.680   0.234   0.770   4.05E-03   2.55E-01   3.43E-06   3.43E-06   1.52   1.13   2.04
  Caucasian *HLA-DQB1\*06:02* negative hypersomnia   108          126             30          264            632                             836         292   1760   0.648   0.352   0.597   0.403   2.51E-02   3.00E-02   1.16E-01   2.51E-02   1.25   1.03   1.52
  Japanese narcolepsy                                37           161             211         409            92                              590         878   1560   0.287   0.713   0.250   0.750   2.22E-02   8.93E-02   2.20E-02   2.20E-02   1.22   1.03   1.45
  Caucasian narcolepsy                               439          503             151         1093           519                             625         235   1379   0.632   0.368   0.600   0.400   3.89E-02   2.82E-02   2.00E-01   2.82E-02   1.13   1.01   1.27

**Notes.**

AF: allele frequency; OR: Odds Ratio; L95,U95: lower and upper limits of confidence interval at 95%; *P*~min~: minimum *P*-value among three genetic models.

Recessive model is calculated under risk allele homozygotes versus (heterozygous and non-risk homozygotes).

Dominant model is calculated under (risk allele homozygotes and heterozygotes) versus non-risk homozygotes.

Discussions
===========

This study represents the first GWAS designed to identify common genetic variants that are associated with EHS in a Japanese population; 125 individuals with EHS and 562 healthy controls participated in this study. We identified novel candidate regions associated with an increased risk of EHS in this Japanese population.

Several SNPs located in an intron of *NCKAP5* gene showed associations with an increased risk of EHS in this study. *NCKAP5* variants are reportedly strongly associated genes with bipolar disorder ([@ref-34]), attention deficit hyperactivity disorders ([@ref-19]), and multiple sclerosis ([@ref-3]). Further meta-analysis of combination of schizophrenia and bipolar disorder confirmed the association between *NCKAP5* variants and both schizophrenia and bipolar disorder ([@ref-36]). Currently, the function of *NCKAP5* is unknown.

*SPRED1* was the gene closest to the SNP with the second highest *P*-value by regional based; *SPRED1* is a member of the Sprouty family of proteins and is known to be phosphorylated by a tyrosine kinase in response to several growth factors ([@ref-9]). Proteins in the *SPRED1* family act as negative regulators of RAS-RAF interactions and of the mitogen-activated protein kinase (MAPK) signaling pathway ([@ref-7]). RAS/MAPK signaling has been implicated in the mediation of reversible circadian outputs ([@ref-37]) and sleep/wake condition mechanism ([@ref-12]) of the brain. Some narcolepsy without cataplexy patients have been reported to exhibit down-regulation of lumbar cerebrospinal fluid hypocretin-1 level ([@ref-6]) and hypothalamic peptides hypocretin/orexin has been reported to contribute to the intrusion of REM sleep behaviors into wakefulness by coordinating the activity of RAS through hypocretin/orexin neuron during waking stage ([@ref-8]). Since *SPRED1* is an important component in the RAS pathway, *SPRED1* might play a crucial role in regulating REM sleep behaviors. In addition, germline mutations in genes involved in the RAS pathway lead to neuro-cardio-facial-cutaneous (NCFC) syndromes (ex: neurofibromatosis 1 (NF1, OMIM 162200) ([@ref-7]), Noonan syndrome (NS, OMIM 163950), LEOPARD syndrome (LS, OMIM 151100), cardio-facio-cutaneous syndrome (CFC, OMIM 115150), and Costello syndrome (CS, OMIM 218040) ([@ref-30])). The SNP rs11854769 was identified in a recent GWAS of bipolar disorder ([@ref-13]); this finding may indicate that this *SPRED1* variant may confer a genetic predisposition for multiple neuropsychiatric diseases.

Association studies for rs10988217 in *CRAT* showed significant associations with both EHS and narcolepsy with cataplexy patients. In addition, these associations were observed not only in Japanese but also in Caucasians ([Table 3](#table-3){ref-type="table"}). These results indicated that *CRAT* may be a susceptibility gene for different types of hypersomnias. The eQTL analysis of rs10988217 revealed that the SNP was associated with alterations in the expression of *CRAT* ([Figs. S3B](#supp-3){ref-type="supplementary-material"}, [S4B](#supp-4){ref-type="supplementary-material"}). Besides the *CRAT* association in our study, interestingly, a recent GWAS ([@ref-26]) for narcolepsy with cataplexy in a Japanese population identified a significant association between a SNP adjacent to *CPT1B* (carnitine palmitoyltransferase 1B). This SNP is also associated with changes in *CPT1B* expression levels ([@ref-26]). Furthermore, a subsequent association study demonstrated an association between *CPT1B* and EHS ([@ref-23]). Both CRAT and CPT1B are involved in the β-oxidation of fatty acid. CRAT gene encodes the carnitine acetyltransferase protein, which is a key enzyme in the β-oxidation pathway in mitochondria, peroxisomes, and the endoplasmic reticulum. CRAT is responsible for catalyzing the reversible transfer of acyl compartments groups from an acyl-CoA thioester to carnitine, and this enzyme regulates the ratio of acylCoA/CoA in the subcellular compartments ([Fig. S5](#supp-5){ref-type="supplementary-material"}). CPT1B is the rate-controlling enzyme of long-chain fatty acid β-oxidation in the mitochondria of muscle tissue. CPT1B catalyzes the transport of long-chain fatty acyl-CoAs from the cytoplasm into the mitochondria through the carnitine shuttle ([Fig. S5](#supp-5){ref-type="supplementary-material"}). Deficiency of short-chain acyl-coenzyme A dehydrogenase in a mouse model resulted in slowing of theta frequency during REM sleep ([@ref-35]). Additionally, acetyl-L-carnitine (ALCAR) is a potential treatment for neurological diseases such as Parkinson's disease ([@ref-5]) and Alzheimer's disease ([@ref-28]); it is also known to restore β-oxidation of fatty acids in the mitochondria and rescued the slow theta frequency in REM sleep of mice lacking short-chain acyl-coenzyme A dehydrogenase ([@ref-35]). Besides, our group has recently reported a clinical trial of oral L-carnitine on narcolepsy with cataplexy and the results suggested that oral L-carnitine can be a promising treatment for narcolepsy with cataplexy ([@ref-25]; [@ref-27]). On the basis of these reports, the results in our study indicated that the pathophysiology of hypersomnias is associated with metabolic alterations ([@ref-25]; [@ref-27]).

For rs10988217 in *CRAT*, the best *p*-values in Japanese EHS and narcolepsy with cataplexy patients were from the recessive model ([Table 3](#table-3){ref-type="table"}). The recessive model was not significant in Caucasian hypersomnia and narcolepsy with cataplexy patients, but the allelic model showed a significant association ([Table 3](#table-3){ref-type="table"}). This might be due to a difference between the populations. In addition, the risk allele (G) for rs10988217 was minor in Japanese but major in Caucasians ([Table 3](#table-3){ref-type="table"}). As another possibility, rs10988217 is not the primary SNP of *CRAT* region. LD of the primary SNP and rs10988217 might be different between Japanese and Caucasian, contributing to the different significant model. Therefore, a further replication study and re-sequencing should be required to overcome the limitations.

Conclusion
==========

In summary, we report associations of *NCKAP5*, *SPRED1*, and *CRAT* variants with *HLA-DQB1\*06:02* negative EHS as novel candidate loci that have not been reported in other GWAS. In addition, our results showed that *CRAT* might act as a susceptibility gene for a variety of hypersomnia disorders. Further additional replication is warranted for confirmation of this study.

Supplemental Information
========================
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###### Q--Q plot of GWAS data from the patients with HLA-DQB1\*06:02 negative EHS in the Japanese population. Q--Q plot was plotted based on Conchran--Armitage trend *P*-values after standard quality control (genomic inflation factor λ = 1.008).

###### 

Click here for additional data file.
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###### Manhattan plot of the GWAS data from the Japanese population.

Manhattan plot was plotted based on *P*-value calculated using the Cochran--Armitage trend test.

###### 

Click here for additional data file.
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###### 

eQTL analyses were performed based on data from the Sanger Institute GENEVAR project^14^, this expression data is based on three cell types (fibroblast, lymphoblastoid cell line, and T-cell) from 75 unrelated individuals of Western European ancestry. (A) The plot displays the relationship between *SPRED1* gene expression and rs11854769. (B) The plot displays the relationship between *CRAT* gene expression and rs10988217. (C) The plot displays the relationship between *PPP2R4* gene expression and rs10988217.

###### 

Click here for additional data file.
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###### 

eQTL association analyses were performed based on transcript expression data from the SNPExpress Database; these data were derived from brain samples from 93 individuals of European ancestry (left) and Peripheral Blood Mononuclear Cell (PMBC) sample. (A) The plot displays the relationship between *SPRED1* gene expression and rs11854769. (B) The plot displays the relationship between *CRAT* gene expression and rs10988217. (C) The plot displays the relationship between *PPP2R4* gene expression and rs10988217.

###### 

Click here for additional data file.

10.7717/peerj.66/supp-5

###### Fatty acid synthesis, beta-oxidation and carnitine shuttle pathways in relation to *CRAT* and *CPT1B*.

###### 

Click here for additional data file.
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